Philip James Wealth Mangement LLC Takes $4.38 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Philip James Wealth Mangement LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, Holdings Channel reports. The institutional investor purchased 52,291 shares of the biopharmaceutical company’s stock, valued at approximately $4,384,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. boosted its holdings in Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares during the last quarter. nVerses Capital LLC bought a new stake in Gilead Sciences during the third quarter worth about $25,000. Valued Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares in the last quarter. Cedar Wealth Management LLC boosted its stake in shares of Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 160 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences during the 2nd quarter worth $33,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 62,437 shares of company stock worth $5,374,825. Insiders own 0.29% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock traded down $0.74 during trading on Friday, hitting $97.16. The company’s stock had a trading volume of 1,305,828 shares, compared to its average volume of 7,018,425. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.32. The company has a market cap of $120.96 billion, a PE ratio of 118.29, a P/E/G ratio of 3.13 and a beta of 0.17. The business has a fifty day moving average of $84.58 and a 200-day moving average of $74.67. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.29 earnings per share. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be issued a $0.77 dividend. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.17%. Gilead Sciences’s dividend payout ratio (DPR) is presently 375.61%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on GILD. Royal Bank of Canada raised their price target on shares of Gilead Sciences from $75.00 to $81.00 and gave the company a “sector perform” rating in a research note on Thursday. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. BMO Capital Markets increased their price target on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday. Oppenheimer lifted their price objective on Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Sanford C. Bernstein began coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price for the company. Twelve equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.71.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.